Literature DB >> 19622001

Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation.

B G Lake1.   

Abstract

Phenobarbitone and related compounds induce hepatic microsomal cytochrome P450 (CYP) 2B forms (mediated by the constitutive androstane receptor), whereas peroxisome proliferators induce CYP4A forms (mediated by the peroxisome proliferator-activated receptor alpha) in rats and mice. A number of non-genotoxic CYP2B and CYP4A inducers have been shown to produce liver tumours in rats and mice. The hepatic effects of CYP2B and CYP4A inducers are reviewed and evaluated with respect to their established modes of action for rodent liver tumour formation and species differences in response. While CYP2B and CYP4A inducers stimulate replicative DNA synthesis in rodent liver, they do not appear to be mitogenic agents in human hepatocytes. Epidemiological studies have demonstrated that phenobarbitone and rodent peroxisome proliferators do not increase the incidence of liver tumours in humans. It is concluded that rodent CYP2B and CYP4A inducers do not pose a hepatocarcinogenic hazard for humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622001     DOI: 10.1080/00498250903098184

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  16 in total

Review 1.  Small-molecule modulators of the constitutive androstane receptor.

Authors:  Milu T Cherian; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-05-15       Impact factor: 4.481

2.  Perfluorooctane sulfonate alters gut microbiota-host metabolic homeostasis in mice.

Authors:  Limin Zhang; Bipin Rimal; Robert G Nichols; Yuan Tian; Philip B Smith; Emmanuel Hatzakis; Shu-Ching Chang; John L Butenhoff; Jeffrey M Peters; Andrew D Patterson
Journal:  Toxicology       Date:  2020-01-08       Impact factor: 4.221

Review 3.  Case examples of an evaluation of the human relevance of the pyrethroids/pyrethrins-induced liver tumours in rodents based on the mode of action.

Authors:  Tomoya Yamada
Journal:  Toxicol Res (Camb)       Date:  2018-01-16       Impact factor: 3.524

4.  Candidate genes responsible for early key events of phenobarbital-promoted mouse hepatocellular tumorigenesis based on differentiation of regulating genes between wild type mice and humanized chimeric mice.

Authors:  Ayako Ohara; Yasuhiko Takahashi; Miwa Kondo; Yu Okuda; Shuji Takeda; Masahiko Kushida; Kentaro Kobayashi; Kayo Sumida; Tomoya Yamada
Journal:  Toxicol Res (Camb)       Date:  2017-08-24       Impact factor: 3.524

Review 5.  Human relevance of rodent liver tumour formation by constitutive androstane receptor (CAR) activators.

Authors:  Brian G Lake
Journal:  Toxicol Res (Camb)       Date:  2018-03-12       Impact factor: 3.524

6.  Application research on PPARα-transgenic mice in preclinical safety evaluation of gemfibrozil.

Authors:  Yan Li; Hongmei Mao; Yanfeng Xu; Xiaocen Li; Lishan Pan; Xin Wu; Yang Li; Yi Li; Jun He
Journal:  Toxicol Res (Camb)       Date:  2016-11-07       Impact factor: 3.524

Review 7.  Small-molecule modulators of PXR and CAR.

Authors:  Sergio C Chai; Milu T Cherian; Yue-Ming Wang; Taosheng Chen
Journal:  Biochim Biophys Acta       Date:  2016-02-24

8.  Phenobarbital and propiconazole toxicogenomic profiles in mice show major similarities consistent with the key role that constitutive androstane receptor (CAR) activation plays in their mode of action.

Authors:  Richard A Currie; Richard C Peffer; Amber K Goetz; Curtis J Omiecinski; Jay I Goodman
Journal:  Toxicology       Date:  2014-03-24       Impact factor: 4.221

Review 9.  Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator.

Authors:  Clifford R Elcombe; Richard C Peffer; Douglas C Wolf; Jason Bailey; Remi Bars; David Bell; Russell C Cattley; Stephen S Ferguson; David Geter; Amber Goetz; Jay I Goodman; Susan Hester; Abigail Jacobs; Curtis J Omiecinski; Rita Schoeny; Wen Xie; Brian G Lake
Journal:  Crit Rev Toxicol       Date:  2013-11-04       Impact factor: 5.635

10.  Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism.

Authors:  Michael L Cunningham; Bradley J Collins; Milton R Hejtmancik; Ronald A Herbert; Gregory S Travlos; Molly K Vallant; Matthew D Stout
Journal:  PPAR Res       Date:  2010-10-04       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.